Recombinant EGFR (Nimotuzumab Biosimilar) antibody

Catalog No. ABIN7795094

This Humanized Monoclonal antibody specifically detects EGFR (Nimotuzumab Biosimilar) in FACS and in vivo. It exhibits reactivity toward Human.

Quick Overview for Recombinant EGFR (Nimotuzumab Biosimilar) antibody (ABIN7795094)

Target: EGFR (Nimotuzumab Biosimilar)

Antibody Type: Recombinant Antibody

Reactivity: Human

Host: Humanized

Clonality: Monoclonal

Conjugate: This EGFR (Nimotuzumab Biosimilar) antibody is un-conjugated

Application: Flow Cytometry (FACS), In vivo Studies (in vivo)

Grade: Research Grade

Product Details anti-EGFR (Nimotuzumab Biosimilar) Antibody

Expression System: Mammalian cells

Purpose: Nimotuzumab Biosimilar, EGFR Monoclonal Antibody

Characteristics: Nimotuzumab Biosimilar uses the same protein sequences as the therapeutic antibody nimotuzumab. Like cetuximab, nimotuzumab is a humanized monoclonal antibody that binds to the epidermal growth factor receptor (EGFR), a signalling protein that normally controls cell division. In some cancers, this receptor is altered to cause uncontrolled cell division, a hallmark of cancer. These monoclonal antibodies block EGFR and stop the uncontrolled cell division. It has a humanized human-mouse h-R3 heavy chain and a humanized human-mouse h-R3 κ-chain. Nimotuzumab binds with optimal affinity and high specificity to the extracellular region of EGFR (epidermal growth factor receptor). This results in a blockade of ligand binding and receptor activation. Epidermal growth factor receptor (EGFR) is a key target in the development of cancer therapeutics. EGFR-targeting drugs have been shown to improve response when used with conventional treatments such as radiation therapy and chemotherapy.

Purification: Protein A or G affinity column

Purity: >95 % by reducing SDS-PAGE

Endotoxin Level: < 1 EU per 1 mg of the protein by the LAL method

Immunogen: Human EGFR / ErbB-1

Application Details

Application Notes: Optimal working dilution should be determined by the investigator.

Restrictions: For Research Use only

Handling

Format: Liquid

Concentration: > 3 mg/mL

Storage: 4 °C,-20 °C

Storage Comment: Short time 2 to 8°C as supplied. Long time -20°C to -70°C as supplied.

Target Details for EGFR (Nimotuzumab Biosimilar)

Target: EGFR (Nimotuzumab Biosimilar)

Alternative Name: Nimotuzumab Biosimilar

Target Type: Biosimilar